Once daily sustained release tablets of venlafaxine, a novel antidepressant

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 54, Issue 1, 2002, Pages 9-15

  Makhija, Sapna N ^a   Vavia, Pradeep R ^a  

^a UNIVERSITY OF MUMBAI   (India)

Author keywords

Cellulose acetate; Ethylcellulose; Eudragit RSPO; Hydroxypropylmethylcellulose; In vivo studies; Matrix system; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CELLULOSE ACETATE; ETHYL CELLULOSE; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE; POLYMER; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG SCREENING; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; HUMIDITY; HYDROGEL; MATRIX TABLET; NORMAL HUMAN; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; TEMPERATURE; THICKNESS; VOLUNTEER; WEIGHT; AREA UNDER THE CURVE; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION;

ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; COMPARATIVE STUDY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; HUMAN; METHYLCELLULOSE; POLYMERS; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035985868     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(02)00049-8     Document Type: Article

References (15)

1. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
2. Inhibition of noradrenergic neuronal activity by the novel bicyclic compounds, Wy-45,030 and Wy-45,881
3. Biochemical, neurophysiological and behavioural effects of Wy-45,233, its enantiomers and other identified metabolites of the antidepressant venlafaxine
4. Binding of antidepressants to human brain receptors: Focus on newer generation compounds
5. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ether cyclohexanol derivative
6. The pharmacokinetics of venlafaxine when given in a twice-daily regimen
7. Extension of the international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV
8. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
9. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine
10. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam
11. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium
12. Rapid determination of venlafaxine and o-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection
13. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and o-desmethylvenlafaxine in biological fluids
14. Relationship between swelling and drug release in a hydrophilic matrix